Recent Updates
Recently added Catalysts
NBIX Neutral Sentiment Score: 60/100

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2024 financial results conference call and...

Key Takeaway: Neurocrine Biosciences, Inc. has scheduled a conference call and webcast to discuss its second quarter 2024 financial results, set for August 1, 2024. The press release is scheduled to be available at 4:00 a.m. PT, followed by the call at 5:00 a.m. PT. Interested parties can access the webcast via the company's website. Neurocrine focuses on developing treatments for various neurological disorders and has a range of products already on the market.

Market Sentiment Analysis

POSITIVE FACTORS

  • Neurocrine Biosciences is engaged in valuable financial updates.
  • The company has a diverse portfolio of FDA-approved treatments.
  • The schedule for the conference call is clearly outlined.

Full Press Release Details

Conference Call and Webcast Scheduled for Thursday, August 1
SAN DIEGO , July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it has scheduled its second quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time ( 8:00 a.m. Eastern Time ) on August 1, 2024 .
The schedule for the press release and conference call / webcast is as follows:
Q2 2024 Press Release: August 1, 2024 at 4:00 a.m. PT / 7:00 a.m. ET
Q2 2024 Conference Call: August 1, 2024 at 5:00 a.m. PT / 8:00 a.m. ET
Domestic Dial-In Number: 800-445-7795
International Dial-In Number: 785-424-1699
Conference ID: NBIX
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com . A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (Formerly Twitter) and Facebook . (* in collaboration with AbbVie )
NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.
SOURCE Neurocrine Biosciences, Inc.

21 %

Frequently Asked Questions

When is the Q2 2024 financial results call scheduled?

The call is set for August 1, 2024, at 5:00 a.m. PT.

What time will the Q2 2024 press release be available?

The press release will be released at 4:00 a.m. PT on August 1, 2024.

How can I access the webcast of the conference call?

The webcast can be accessed on Neurocrine's website under Investors.

What is the domestic dial-in number for the call?

The domestic dial-in number is 800-445-7795.

What types of disorders does Neurocrine focus on?

Neurocrine focuses on neurological, neuroendocrine, and neuropsychiatric disorders.

Last updated: Jul 11, 2024